rare diseases, drug development, AIDS, drug pricing, Orphan Drug Act
In this article, we examine the Orphan Drug Act with an eye toward its contribution to the public interest, using AIDS drugs to illustrate many of the central points. The major policy question is, How, if at all, can the act be used to meet the legislative goal of stimulating drug development for small patient populations without resulting in prices that make drugs inaccessible?
Michael Henry Davis, Peter S. Arno and Karen Bonuck, Rare Diseases, Drug Development and AIDS: The Impact of the Orphan Drug Act, 73 Milbank Quarterly 231 (1995)
© 1995 The Milbank Memorial Fund.